pegol sihematide (EPO-018B) / Jiangsu Hansoh Pharma - LARVOL DELTA

Two Different Regiments of Pegmolesatide for Anemia in Patients With Chronic Kidney Disease Not Receiving Dialysis (clinicaltrials.gov) - P4 | N=160 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Dalian Medical University

New P4 trial • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on Dialysis (clinicaltrials.gov) - P3 | N=372 | Completed | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Sep 2021 ➔ May 2022

Trial completion • Trial completion date • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With NDD-CKD (clinicaltrials.gov) - P3 | N=175 | Active, not recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown status ➔ Active, not recruiting | Trial completion date: May 2021 ➔ Dec 2022 | Trial primary completion date: Nov 2019 ➔ Oct 2021

Enrollment closed • Head-to-Head • Trial completion date • Trial primary completion date • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on Dialysis (clinicaltrials.gov) - P3; N=330; Recruiting; Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.; Not yet recruiting ➔ Recruiting; Trial completion date: Dec 2020 ➔ Sep 2021; Trial primary completion date: May 2019 ➔ Feb 2021

Enrollment open • Trial completion date • Trial primary completion date • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease